Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

周五，高盛证券调整了对诺和诺德公司股票（NOVOB:DC）（NYSE: NVO）的财务展望，将目标价从798.00丹麦克朗略微上调至798.00丹麦克朗。该公司维持对这家制药公司股票的买入评级。

Guggenheim Securities adjusted its financial outlook for Novo Nordisk (NYSE:NVO) shares (NOVOB:DC) (NYSE: NVO), raising the price target slightly to DKK798.00 from DKK795.00. The firm maintained a Buy ...

This is largely thanks to strong performances from GLP-1 analogue Victoza, insulin analogue Levemir and the 2015 launch of longer-acting insulin analogue Tresiba. Other companies rising strongly ...

Biden cap on drug costs will save US seniors over $1,000 a year, study finds August 28, 2024 Novo Nordisk's decision to stop selling its long-acting insulin Levemir in the United States has left ...

Overall, these top 25 drugs were responsible for nearly $50 billion in total Medicare Part D spending in 2022, AARP finds.